Sherbrooke, QC, January 27th, 2026 – EncephalX, a Canadian medtech company, has closed a CAD $2.25M oversubscribed pre-seed round to support its mission: redefining the standard of care for patients suffering from traumatic brain injury and stroke. EncephalX’s flagship product, the Dynamic Cranioplasty System (DCPS), is designed to replace the current two-step surgical intervention with a safer, single-procedure solution, aiming to improve patient outcomes while reducing hospital stays and overall healthcare system burden. The round was led by ACET Capital, a long-standing collaborator through its second fund – ACET Capital 2, with participation from Investissement Québec, Anges Québec and HaloHealth.
EncephalX was founded at the intersection of engineering innovation and unmet clinical need, shaped by direct input from the neurosurgical community. The company emerged from academic research on cranial defects and evolved through close collaboration with practicing neurosurgeons. Limitations of the conventional procedure were articulated by Dr. Christian Iorio-Morin, neurosurgeon specializing in deep brain stimulation at the CHUS and Medical Director of EncephalX. From patients, to hospitals, to healthcare professionals, there was a pressing need for a safer postoperative solution.
“This new technology will offer peace of mind for neurosurgeons by providing an option not yet available on the market: continuous intracranial pressure decompression immediately after surgery, while maintaining patient safety,”
explains Dr. Iorio-Morin. This clinician-driven insight laid the foundation for a technology designed to meet real-world operating room constraints.
“This pre-seed round will enable EncephalX to reach a major milestone: the company’s first human implantation. This marks a decisive step toward regulatory approval of our fully developed surgical kit,”
says Simon Lapointe, Founder and CEO of EncephalX.
“EncephalX is transforming the care pathway by consolidating treatment into a single operation, thereby eliminating a second procedure. This approach delivers measurable impact: improved patient quality of life, significant cost reductions for health systems, and streamlined clinical practice for neurosurgeons. From the outset, the team has demonstrated rigorous execution and the discipline to meet each milestone. We are proud to support EncephalX on its path toward establishing a new standard of care with strong potential for scale,”
notes Dominic Denis, Investment Director at ACET Capital.
“This announcement highlights the full potential of public research commercialization in Québec. Promising young companies like EncephalX are proving that success can be built here. Our government is therefore proud to invest $1 million in EncephalX through the Impulsion Fund, an investment that will undoubtedly help improve patients’ quality of life,”
says Samuel Poulin, Minister Responsible for Youth and Associate Minister of the Economy and Small and Medium-Sized Enterprises.
“The life sciences sector plays a critical role in Québec’s economic vitality and in the emergence of innovative solutions. Through the Impulsion Fund, we are able to support companies like EncephalX at a pivotal moment in their journey, providing the momentum needed to advance to the next stages of their development,”
says Alex Laverdière, Vice-président, Vice President, Venture Capital at Investissement Québec.
“EncephalX is proposing an innovative approach where a familiar surgical procedure can lead to a game-changing outcome for patient recovery while generating meaningful savings for the healthcare system. As such, we foresee rapid and enthusiastic market adoption of this new technology. Anges Québec is proud to support this promising local initiative,”
says Louis-Georges Guy, Angel Investor at Anges Québec.
“As a physician angel investment group, we only invest in healthcare ventures that pass our rigorous selection process and are purpose-built to improve the lives of patients. We are proud to invest in EncephalX and support Simon in his relentless pursuit of commercializing the Dynamic Cranioplasty System (DCPS),”
notes Luke Sheen, Founding Executive Director of HaloHealth.
Looking ahead
With this pre-seed round closed, EncephalX is advancing toward first-in-human use while continuing to build partnerships across clinical, regulatory, and industrial domains. The company’s long-term ambition is to scale its technology internationally and establish a new standard of care in neurosurgery.
Media contact: Simon Lapointe, Founder & CEO EncephalX
Email: info@encephalx.ca, Website: info@encephalx.ca
